PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today the publication of a darinaparsin (Zinapar® or ZIO-101) study in the PLoS ONE, an international, peer-reviewed, open-access, online publication of the Public Library of Science. The publication, titled "Darinaparsin Is a Multivalent Chemotherapeutic Which Induces Incomplete Stress Response with Disruption of Microtubules and Shh Signaling," was conducted by a Vanderbilt University Medical Center research team from the Departments of Cell and Developmental Biology, the Epithelial Biology Center, and Department of Surgery.

“Darinaparsin Is a Multivalent Chemotherapeutic Which Induces Incomplete Stress Response with Disruption of Microtubules and Shh Signaling”

The study describes darinaparsin's anti-cancer activity as a unique multivalent mitochondrial-targeting agent acting on cell stress induction, microtubule polymerization and sonic hedgehog signaling ("Shh"). The publication concludes that darinaparsin's range of action against these multiple drivers of neoplastic cell proliferation may make this organic arsenical an effective therapy for multiple resistant solid and hematological malignancies. The publication is available online at http://dx.plos.org/10.1371/journal.pone.0027699.

Darinaparsin is currently in a Phase 1 study in solid tumors using an oral formulation.

Source:

 ZIOPHARM Oncology, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Penn Medicine and CHOP announce plans with Costa Rica's CCSS for CAR T research